The global urological cancers market is projected to double by 2022 and reach $35.9bn growing at a compound annual growth rate (CAGR) of 10.39%, up from $17.9bn in 2015, according to a report by GBI Research.

Titled ‘Global Urological Cancer Market to 2022 – Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics‘, the report states that the urological cancers market includes bladder, kidney, prostate and testicular cancers and the growth of this space will be propelled by new targeted therapies for bladder cancer.

The increase in market value will also be supported by the growing incidence of prostate and kidney cancer.

New checkpoint inhibitors are expected to be introduced to help in reducing the associated toxicity of urological cancer therapies.

"Key players Johnson & Johnson and Pfizer … are predicted to have decreasing market shares due to decreasing or static drug revenues as the overall market revenues rise."

They will be increasingly used for treating patients with low functional status.

The launch of targeted therapies will enhance the survival chances of the patients and enable the administration of an increased number of chemotherapy rounds.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The treatment space of urological cancer will be reshaped by the launch of Roche’s atezolizumab and AstraZeneca‘s durvalumab for the treatment of bladder cancer. The two drugs are projected to capture the market, with atezolizumab anticipated to achieve revenue of $2.5bn in 2022 and durvalumab positioned to generate $1.2bn.

Roche’s drug is expected to receive approval later this year, while AstraZeneca will receive approval for its drug in 2017. The success of these drugs will be largely driven by a lack of targeted treatment for bladder cancer and a rise in the number of cases.

The introduction of these drugs is expected to alter the market landscape, while the currently available drugs will continue to dominate in terms of revenue, due to market competition.

Analyst for GBI Research Adam Bradbury explains: "Key players Johnson & Johnson and Pfizer, for example, are predicted to have decreasing market shares due to decreasing or static drug revenues as the overall market revenues rise.

"Those of Roche and Bristol-Myers Squibb (BMS), on the other hand, will increase due to the uptake of recently approved and upcoming immune checkpoint inhibitors such as atezolizumab, and BMS’s Opdivo and Yervoy.

"Astellas is forecast to maintain its strong market share through to 2022 due to increasing Xtandi revenues."